Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440011 · ClinicalTrials.gov registry record · Phase 4
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
A Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 266
- Enrollment target
- 1
- Study location
NCT00440011: Completed Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
NCT00440011 is a Phase 4 study of Glaucoma and Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 266 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00440011, a Phase 4 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 266 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
Primary Outcome
Intraocular Pressure
Conditions Studied
Interventions
- DRUG bimatoprost 0.03% eye drops
- DRUG travoprost 0.004% eye drops
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
What the finished NCT00440011 record still lists
NCT00440011 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which bimatoprost 0.03% eye drops is the first listed.
NCT00440011 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00440011 about?
NCT00440011 is a clinical study titled "Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%". Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
What is the current status of trial NCT00440011?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 266 participants. The study started on 2006-08. Estimated completion is 2007-10.
What conditions does trial NCT00440011 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00440011?
The interventions under investigation include: bimatoprost 0.03% eye drops (DRUG), travoprost 0.004% eye drops (DRUG).
Who is sponsoring clinical trial NCT00440011?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00440011 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00440011's enrollment target sits among peer trials
266 20th of 92 higher than 73 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia